Last edition
News about Biotechnology
Cellectar Biosciences Partners with ITM to Secure Actinium-225 Supply for Cancer Drug Development
Cellectar Biosciences, Inc., a late-stage clinical biopharmaceutical company focused on cancer drug discovery and development, has entered into a supply agreement with ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech firm, for Actinium-225 (Ac-225).
Biotechnology | 15/09/2025 | By Darshana | 155
RION Forms INTENT Biologics to Develop Clinical Exosome-Based Therapies
With the launch of INTENT Biologics, RION targets global impact in inflammation care; Suneet Varma named CEO to lead the charge.
Biotechnology | 11/09/2025 | By Dineshwori | 232
Polpharma Biologics Partners with MS Pharma to Commercialize Biosimilars in MENA Region
Polpharma Biologics S.A., a biotechnology company specializing in the development and manufacturing of biosimilars, has entered into licensing agreements with MS Pharma, a leading biosimilar producer and distributor in the Middle East and North Africa (MENA) region.
Biotechnology | 03/09/2025 | By Darshana | 186
Bio-Thera and Gedeon Richter Secure EC Approval for Usymro, a Stelara Biosimilar
Bio-Thera Solutions Inc., a commercial-stage biopharmaceutical company, announced that the European Commission (EC) has approved BAT2206 (ustekinumab), a biosimilar referencing Janssen’s Stelara, following a positive opinion from the EMA’s CHMP on June 19, 2025. The product will be marketed in Europe by Gedeon Richter under the brand name Usymro.
Biotechnology | 28/08/2025 | By Darshana | 185
Marking One Year of BioE3 Policy, Dr. Jitendra Singh launched the BioE3 Challenge for Youth and the country’s first National Biofoundry Network, calling it a step towards making biotechnology a driver of India’s economy, environment and employment.
Biotechnology | 28/08/2025 | By Dineshwori | 202
Aurobindo Pharma Wins UK MHRA Approval for Dazublys Trastuzumab Biosimilar
CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, has received marketing authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its trastuzumab biosimilar, Dazublys, used in the treatment of HER2-positive breast and gastric cancers.
Biotechnology | 27/08/2025 | By Darshana | 182
This marks the third collaboration BioArctic has entered into with partners using the BrainTransporter technology.
Biotechnology | 27/08/2025 | By Dineshwori | 226
Novartis Expands Collaboration with BioArctic, Eyes Licensing Opportunity Worth Up to $772 Million
The partnership focuses on combining BioArctic’s BrainTransporter technology with a Novartis proprietary antibody to develop a novel drug candidate. Should Novartis proceed, it would take full responsibility for the candidate’s global development and commercialization.
Biotechnology | 26/08/2025 | By Darshana | 286
Collaboration Aims to Scale AAV Manufacturing for Rare Neuromuscular Junction Diseases
NMJ disorders often cause severe muscle weakness, with many patients requiring respiratory support, wheelchairs, or tube feeding. These genetic diseases can be life-threatening, often diagnosed in childhood but sometimes appearing later in life.
Biotechnology | 24/08/2025 | By Darshana
Gilead's Kite Acquires Interius BioTherapeutics for USD 350 Million to Fuel In Vivo CAR-T Innovation
Gilead Sciences’ subsidiary Kite Pharma has announced the acquisition of Interius BioTherapeutics, a privately held biotech company, for USD 350 million in cash. The deal is aimed at advancing Kite’s development of in vivo CAR-T cell therapies, considered a next-generation approach to cancer treatment.
Biotechnology | 22/08/2025 | By Darshana | 179
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy